Meeting
2022 ASCO Annual Meeting
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
Presenter
Caicun Zhou, MD, PhD, ABFT
Oncology Department, Shanghai Pulmonary Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03789604
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9027)
DOI
10.1200/JCO.2022.40.16_suppl.9027
Abstract #
9027
Poster Bd #
15
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Speaker: Luis G. Paz-Ares, PhD
Videos & Slides
ASCO Media Events
Presentation of Abstract 5500, KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Speaker: Bradley Monk
Videos & Slides
2023 ASCO Annual Meeting
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Speaker: Heather A. Wakelee, MD, FASCO